Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice
暂无分享,去创建一个
O. Wildner | W. Bayer | M. Tenbusch | T. Niezold | Michael Storcksdieck genannt Bonsmann | R. Lietz | Lena Johrden
[1] Oliver Wildner,et al. Comparison of polystyrene nanoparticles and UV-inactivated antigen-displaying adenovirus for vaccine delivery in mice , 2013, Virology Journal.
[2] S. Himanen,et al. AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland , 2012, PloS one.
[3] Martin F. Bachmann,et al. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns , 2010, Nature Reviews Immunology.
[4] K. Überla,et al. Vaccination with an Adenoviral Vector That Encodes and Displays a Retroviral Antigen Induces Improved Neutralizing Antibody and CD4+ T-Cell Responses and Confers Enhanced Protection , 2009, Journal of Virology.
[5] Y. Shoenfeld,et al. Adjuvants and autoimmunity , 2009, Lupus.
[6] Katrin Schwarz,et al. Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.
[7] K. Überla,et al. Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity , 2008, BMC Immunology.
[8] C. Russell Middaugh,et al. Nanotechnology in vaccine delivery☆ , 2008, Advanced Drug Delivery Reviews.
[9] Sai T Reddy,et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.
[10] Magdalena Plebanski,et al. Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. , 2006, Methods.
[11] Qiang Liu,et al. Molecular basis of the inflammatory response to adenovirus vectors , 2003, Gene Therapy.
[12] W. Egan,et al. Corrigendum to “Aluminum salts in vaccines—US perspective” [Vaccine 20 (Suppl. 2) (2002) S18–S23] , 2002 .
[13] Paul Richman,et al. Aluminum salts in vaccines--US perspective. , 2002, Vaccine.
[14] K. Zatloukal,et al. High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[15] Peter Walden,et al. Exact prediction of a natural T cell epitope , 1991, European journal of immunology.
[16] S. Elsayed,et al. Antigenic and allergenic determinants of ovalbumin--III. MHC Ia-binding peptide (OA 323-339) interacts with human and rabbit specific antibodies. , 1990, Molecular immunology.
[17] H. Waldmann,et al. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo , 1984, Nature.